Glenview Trust Co Acquires 2,990 Shares of Cigna Group $CI

Posted by Stanley Muller on Jul 22nd, 2026

Glenview Trust Co lifted its holdings in Cigna Group (NYSE:CI – Free Report) by 16.8% during the first quarter, HoldingsChannel.com reports. The firm owned 20,777 shares of the health services provider’s stock after purchasing an additional 2,990 shares during the period. Glenview Trust Co’s holdings in Cigna Group were worth $5,542,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Norges Bank bought a new position in Cigna Group in the fourth quarter valued at $1,019,790,000. Northwestern Mutual Wealth Management Co. increased its stake in Cigna Group by 13,333.2% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 3,165,408 shares of the health services provider’s stock valued at $900,912,000 after buying an additional 3,141,844 shares during the last quarter. Dodge & Cox lifted its position in Cigna Group by 19.7% during the 4th quarter. Dodge & Cox now owns 11,138,614 shares of the health services provider’s stock worth $3,065,681,000 after buying an additional 1,833,389 shares in the last quarter. Boston Partners boosted its stake in shares of Cigna Group by 314.6% during the 4th quarter. Boston Partners now owns 1,638,191 shares of the health services provider’s stock worth $450,856,000 after buying an additional 1,243,056 shares during the last quarter. Finally, GQG Partners LLC boosted its stake in shares of Cigna Group by 14.3% during the 4th quarter. GQG Partners LLC now owns 7,763,295 shares of the health services provider’s stock worth $2,136,699,000 after buying an additional 972,302 shares during the last quarter. Institutional investors and hedge funds own 86.99% of the company’s stock.

Cigna Group Stock Up 2.1%

Cigna Group stock opened at $289.82 on Wednesday. The firm has a market capitalization of $76.67 billion, a PE ratio of 12.29, a P/E/G ratio of 1.09 and a beta of 0.29. The company’s 50-day moving average is $286.41 and its 200-day moving average is $280.59. Cigna Group has a fifty-two week low of $239.51 and a fifty-two week high of $315.47. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.73 and a quick ratio of 0.73.

Cigna Group (NYSE:CI – Get Free Report) last issued its earnings results on Thursday, April 30th. The health services provider reported $7.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.60 by $0.19. Cigna Group had a net margin of 2.26% and a return on equity of 19.75%. The company had revenue of $68.52 billion for the quarter, compared to analysts’ expectations of $66.29 billion. During the same period in the prior year, the firm earned $6.74 EPS. Cigna Group’s quarterly revenue was up 4.6% compared to the same quarter last year. Cigna Group has set its FY 2026 guidance at 30.350- EPS. Sell-side analysts anticipate that Cigna Group will post 30.39 earnings per share for the current year.

Insider Activity at Cigna Group

In other Cigna Group news, CEO David Cordani sold 201,878 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $292.82, for a total value of $59,113,915.96. Following the sale, the chief executive officer owned 34,337 shares in the company, valued at $10,054,560.34. This represents a 85.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Jamie G. Kates sold 899 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $298.61, for a total value of $268,450.39. Following the completion of the sale, the chief accounting officer directly owned 2,368 shares of the company’s stock, valued at approximately $707,108.48. The trade was a 27.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Wall Street Zen raised Cigna Group from a “hold” rating to a “buy” rating in a research report on Saturday, June 20th. Jefferies Financial Group reduced their price target on Cigna Group from $333.00 to $330.00 and set a “buy” rating for the company in a research report on Monday, April 20th. Piper Sandler decreased their price target on Cigna Group from $370.00 to $346.00 and set an “overweight” rating for the company in a research note on Wednesday, June 3rd. Wolfe Research reaffirmed an “outperform” rating and set a $315.00 price target on shares of Cigna Group in a research report on Tuesday, June 16th. Finally, Guggenheim upped their price objective on Cigna Group from $334.00 to $338.00 and gave the stock a “buy” rating in a research note on Monday, May 4th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $338.80.

Get Our Latest Stock Report on CI

Cigna Group Company Profile

(Free Report)

Cigna Group (NYSE: CI) is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers.

In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes.